Foveal LLP Independent Investment Research Foveal Research

The first factor XIa clinical efficacy for stroke prevention was presented at the European Society of cardiology in Barcelona yesterday...

We undertake a detailed analysis of seven near term Roche pipeline assets, spanning Roche’s market leading positions in Non-Hodgkin lymphoma to breakthroughs for Duchene muscular dystrophy and find unique assets, but also successful competition

Roche recently announced the failure of co-primary progression free survival endpoints in both of its 1st line TIGIT trials in non-small (SK

ASCO2022 saw the eventual presentation of Pfizer's PALOMA-2 study, where, as we highlighted in our February 2020 Foveal report NOVN...

ASCO 2022 saw publication of new data for Bristol's CD-19 CAR-T Breyanzi (liso cel) in large cell non-Hodgkin’s lymphoma, along with...

We present an update on the state of the factor XI competitive market, building upon our previous analysis of three factor XI inhibitors for

We present an update to our September 2020 detailed pipeline analysis “J&J NME pipeline”, examining the prospects of three new molecular ent

While uncharted territory inhibiting poorly investigated factor XIa, novel mechanism of action and early data and epidemiological studies suggest it could become the gold standard in Stroke prevention.

Last night the FDA granted accelerated approval for Merck’s Keytruda to be used in combination with pemetrexed and carboplatin chemo for...

Predictable failure of ROG anti PDL1 Tecentriq in Bladder cancer where anti PD1 succeeded: As we feared, Roche today announced that its...